Additionally, the Runx2 inhibitor decreased proliferation and enhanced apoptosis in Hepa1-6 cancer cells, suggesting that Runx2 inhibition not only improves CD8+ T-cell function but also suppresses growth in cancer cells, potentially enhancing the efficacy of immunotherapy (Fig. S14). Here, CD8A is linked to cancer.